Mycoplasma Testing Market Outlook:
Mycoplasma Testing Market size was over USD 850.7 million in 2024 and is estimated to reach USD 2.7 billion by the end of 2034, expanding at a CAGR of 10.8% during the forecast timeline, i.e., 2025-2034. In 2025, the industry size of mycoplasma testing is assessed at USD 940.5 million.
The market is remarkably influenced by the increasing need for biologics, cell therapies, and vaccines. Testifying to the same, in 2023, the World Health Organization (WHO), every year, more than 20.6 million patients rely on biologics such as monoclonal antibodies and recombinant proteins. As all of these therapies require stringent contamination testing during production, the expansion of these industries is fueling this sector. This can be exemplified by the U.S. FDA requiring mycoplasma testing for all cell-based therapies, affecting over 507 clinical trials worldwide in 2024. This dual expansion in patient pool and strict compliance requirements underscores the future increase in the use of this technology in drug safety and efficacy.
However, the rising occurrence of financial exhaustion among manufacturers and consumers is hindering affordability and hence the adoption rate in the market. For instance, from 2023 to 2024, the Bureau of Labor Statistics (BLS) recorded a 4.6% year-over-year (YoY) rise in the producer price index (PPI) for essential components. Elevation in supply chain challenges and R&D expenditures was the major reason behind this inflation, which concurrently caused a 4.1% increase in the consumer price index (CPI) for diagnostic services. Moreover, the growing demand for contamination-free production is underscoring the urgent need for optimization of the compliance processes and biopharmaceutical manufacturing.
